IL33 and neoplasm: We next examined the surface phenotype changes of the splenic cDC1s from IL-33-treated tumor-free (TF) mice with typical cDC1 markers and found that CD103 expression was markedly enhanced, whereas the other cDC1 markers were minimally affected by recombinant IL-33 (Fig. 1D).